Imperial College London
Portrait Picture

ProfessorNickHopkinson

Faculty of Medicine, National Heart & Lung Institute

Professor of Respiratory Medicine
 
 
 
//

Contact

 

n.hopkinson

 
 
//

Location

 

Muscle LabSouth BlockRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Hopkinson:2022:10.1136/thoraxjnl-2021-218328,
author = {Hopkinson, N},
doi = {10.1136/thoraxjnl-2021-218328},
journal = {Thorax},
title = {Vectura and Philip Morris – the leopard hasn’t changed its spots.},
url = {http://dx.doi.org/10.1136/thoraxjnl-2021-218328},
volume = {77},
year = {2022}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - The uniquely lethal nature of the tobacco industry’s products, the industry’s environmental impact and its incompatibility with human rights make the takeover of Vectura, a pharmaceutical company focused on inhaler technology, by tobacco giant Philip Morris International (PMI), extremely unwelcome. The idea that a company which, based on its market share and the global death toll, kills more than a million people every year4 should be allowed to expand into the delivery of healthcare has been widely condemned, including by the British Thoracic Society, the European Respiratory Society and the US COPD Foundation, as well as the American Lung Association and American Thoracic Society who referred to the move as “reprehensible”.
AU  - Hopkinson,N
DO  - 10.1136/thoraxjnl-2021-218328
PY  - 2022///
SN  - 0040-6376
TI  - Vectura and Philip Morris – the leopard hasn’t changed its spots.
T2  - Thorax
UR  - http://dx.doi.org/10.1136/thoraxjnl-2021-218328
UR  - https://thorax.bmj.com/content/77/6/537
UR  - http://hdl.handle.net/10044/1/93157
VL  - 77
ER  -
Download